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 ABSTRACT 
 The objectives of this study were to evaluate efficacy 
of a 2-dose regimen of ceftiofur crystalline free acid 
sterile suspension (CCFA-SS) for treatment of acute 
metritis in lactating dairy cows under field conditions 
and to provide additional safety and injection site toler-
ance data for injections at the base of the ear. Cows at 
15 dairies with rectal temperature ≥39.5°C and fetid 
uterine discharge ≤10 d postcalving were randomly 
assigned by blocks of 2, based on order of entry and 
without regard to parity, to treatment with saline (1.5 
mL/45.5 kg of body weight, n = 509) or CCFA-SS (6.6 
mg of ceftiofur equivalents/kg of body weight, n = 
514). Treatments were administered by subcutaneous 
injection in the posterior aspect of the ear where it 
attaches to the head; the first dose was administered 
on study d 0 and the second dose was administered in 
the contra lateral ear on study d 3. Rectal temperatures 
were recorded on study d 1 to 4 and 5 or 6 and cows 
were clinically evaluated daily from study d 1 to 13. 
Cows that exhibited increased adverse clinical signs of 
poor health or complications associated with metritis 
were categorized as a treatment failure and adminis-
tered escape therapy. Each cow received a veterinary 
physical examination on study d 5 or 6 to determine if 
she should be removed from the study and on study d 
14 to determine clinical cure or failure to cure. Clinical 
cure was defined as rectal temperature <39.5°C and 
non-fetid and purulent or mucopurulent discharge on 
study d 14 and no escape therapy administered. The 
injection procedure was scored after each injection 
(study d 0 and 3) and injection sites and ear carriage 
were scored on study d 5 or 6, 14, and 57 ± 3. Of the 
1,023 cows enrolled, 7 were completely censored due to 
protocol deviations and 34 were removed for protocol 
deviations or medical conditions not related to metritis. 
Clinical cure rate was higher for CCFA-SS than for 
saline (74.3 vs. 55.3%) and rectal temperatures for each 
of study d 1 to 5 or 6 were lower for CCFA-SS than 
saline. Injection procedure indices showed that CCFA-
SS could be practically and safely administered using 
commercial dairy facilities. Although injection site 
scores were higher for CCFA-SS than saline at study d 
5 or 6 and 14, ≥98.6% of ears were normal on d 57 ± 
3. Thus, a 2-dose treatment with CCFA-SS given 72 h 
apart increased metritis clinical cure rate and was well 
tolerated in dairy cows. 
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 INTRODUCTION 
 Acute post parturient metritis (acute metritis; also 
known as acute puerperal metritis) is a common dis-
ease of dairy cows and is associated with significant 
economic losses because of the sequelae of reduced 
milk production, poorer reproductive performance, 
and increased risk of culling (LeBlanc et al., 2002; 
Overton and Fetrow, 2008; Wittrock et al., 2011). 
Sheldon et al. (2006) have defined puerperal metritis 
as an abnormally enlarged uterus and a fetid watery 
red-brown discharge associated with signs of systemic 
illness (decreased milk yield, dullness, or other signs of 
toxemia) and fever (temperature >39.5°C) within 21 d 
after calving. The reported incidence of metritis ranges 
widely from 10 to 36% in dairy cows (Stevenson and 
Call, 1988; Borsberry and Dobson, 1989; LeBlanc et 
al., 2002) and a 21% incidence rate of metritis during 
lactation was found in a large survey including 97,316 
cows with 181,322 lactations (Zwald et al., 2004). 
 Specific bacteria identified in the uterus of dairy cat-
tle with metritis include Escherichia coli, Arcanobacte-
rium pyogenes, Fusobacterium necrophorum, Prevotella 
spp., and Bacteroides spp. (Huszenicza et al., 1999; 
Sheldon et al., 2004b; Bicalho et al., 2011). Sheldon 
et al., (2004a), using 20 to 22 strains of bacteria iso-
lated from uteri of postpartum cows with pyrexia and 
or metritis determined MIC90 [minimum concentration 
(in vitro) that will inhibit 90% of the strains of the 
organism tested] values for 6 antibiotics used to treat 
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metritis; MIC90 values for ceftiofur were 0.5 μg/mL for 
E. coli and 0.125 μg/mL for both A. pyogenes and F. 
necrophorum. Thus, metritis treatments include the 
use of systemic antibiotics, specifically cephalosporins 
(Zhou et al., 2001; Chenault et al., 2004) and uterine 
antimicrobial boluses (Smith et al., 1998; Drillich et 
al., 2001) to maintain concentrations above the MIC90 
values for the specific pathogens.
Treatment of cows having a rectal temperature 
≥39.5°C within 10 d of calving with 1-mg ceftiofur 
equivalents (CE) of ceftiofur sodium or chloride per 
kilogram of BW for 3 d increased cure rate of cows that 
also had a vaginal discharge at enrollment compared 
with saline-treated controls (56.0 vs. 28.9%, respec-
tively; Zhou et al., 2001). In addition, cows with toxic 
puerperal metritis treated with 600-mg CE of ceftiofur 
hydrochloride (approximately 1-mg CE/kg of BW) 
given i.m. for 3 d with or without intrauterine antibiot-
ics (2,500 mg of ampicillin and 600 mg of cloxacillin) 
were equally responsive in terms of rectal temperature 
and reproductive performance as cows given 600 mg 
of ampicillin i.m. and intrauterine antibiotics (Drillich 
et al., 2001). In cows enrolled <14 d postpartum with 
rectal temperature ≥39.5°C and fetid vaginal discharge, 
treatment for 5 d with 2.2-mg CE of ceftiofur hydro-
chloride/kg of BW increased clinical cure rate at 14 d 
compared with controls (77 vs. 62%), whereas one-half 
the dose of CE given for 5 d did not have a significant 
effect on clinical cure rate in this US study (Chenault 
et al., 2004). The effects of treatment with 2.2-mg CE 
of ceftiofur sodium/kg of BW administered i.m. for 5 
d to cows with toxic puerperal metritis on rectal tem-
perature on d 1 and 5 and milk yield on d 1 to 12 were 
similar to those of treatment with 22,000 IU of procaine 
penicillin/kg of BW i.m. for 5 d, with or without an 
intrauterine infusion of 6 g of oxytetracycline on d 1, 3, 
and 5 (Smith et al., 1998).
In pharmacokinetic studies, 1-mg CE of ceftiofur 
hydrochloride/kg of BW administered for 1 (Okker 
et al., 2002) or 3 d (Drillich et al., 2006) resulted in 
concentrations of ceftiofur derivatives in serum, lochial 
fluid, endometrium, and caruncles 24 h after the last 
injection that were higher than the MIC90 values re-
ported for E. coli, F. necrophorum, and A. pyogenes, the 
pathogens associated with metritis. It was clear from 
the rate of decrease in the concentrations in uterine tis-
sues that daily injections would be required to maintain 
concentrations above MIC90 levels.
However, successfully delivering daily injections for 
extended periods requires excellent management prac-
tices in a commercial dairy setting. In a recent sur-
vey of 113 dairy herds in Pennsylvania, only 24% of 
producers completed the treatment protocol per label 
for a given condition (Sawant et al., 2005). Ceftiofur 
crystalline free acid sterile suspension (CCFA-SS; 
EXCEDE; Pfizer Animal Health Inc., New York, NY; 
http://pfizerah.com) is approved in the United States 
for the treatment of bovine respiratory disease and foot 
rot when administered as a single dose of 6.6-mg CE of 
CCFA-SS/kg of BW.
It was hypothesized that treatment of metritis with a 
single dose of CCFA-SS would be more convenient than 
5 daily injections of ceftiofur hydrochloride (Excenel 
RTU; Pfizer Animal Health Inc.; http://pfizerah.com) 
and would increase clinical cure rate compared with 
negative controls. However, in a large field trial in the 
United States with similar design as used in the current 
study, a single dose of CCFA-SS did not increase the 
metritis cure rate (J. R. Chenault and M. J. Lucas; 
unpublished data). In addition, it was found that con-
centrations of ceftiofur derivatives in both caruncle and 
endometrial tissue 3 d after a single dose of CCFA-SS 
were less than 0.5 μg/g (M. A. Yancey, J. A. Robinson, 
M. J. Lucas, M. J. Prough, W. L. Bryson, Pfizer Animal 
Health, Kalamazoo, MI; personal communication), the 
MIC90 for E. coli (Sheldon et al., 2004a). Thus, 2 doses 
of CCFA-SS administered 72 h apart were postulated 
to effectively increase clinical cure rate due to extended 
duration of levels of ceftiofur above effective MIC90 lev-
els for bacteria associated with metritis. Thus, a trial 
was conducted to evaluate both the efficacy and safety 
of 2 doses of CCFA-SS given 72 h apart to cows with 
clinical signs of metritis. The injection procedure and 
injection site information were included as measures 
of safety because this was the first registration trial in 
dairy cows in which the route of injection of CCFA-SS 
was the base of the ear.
MATERIALS AND METHODS
All aspects of this study were performed to meet the 
Food and Drug Administration-Center for Veterinary 
Medicine (FDA-CVM) Good Clinical Practice guide 
(FDA-CVM, 2009), except where noted otherwise and 
was conducted under the authorization of Investiga-
tional New Animal Drug (INAD) 10-978. The trial was 
conducted in a manner consistent with applicable lo-
cal, state, and federal laws and regulations governing 
humane care of animals on commercial farms under 
veterinary supervision.
Treatments and Experimental Design
The study was conducted as a multi-dairy random-
ized design with cows blocked by order of entry within 
dairy without regard to parity. The objective was to 
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evaluate the effectiveness of a 2-dose treatment regimen 
of CCFA-SS in cows with acute metritis compared with 
saline-treated controls. Using a 2-sided test at the 0.05 
significance level for a treatment comparison, there was 
an expected 80% power to detect a 10-percentage point 
difference in clinical cure rate using the assumptions 
of 50% clinical cure rate in the saline control group, 
with 15 locations and 30 animals in each of 2 treat-
ment groups at each location included in the statistical 
analysis for effectiveness. Cows meeting enrollment 
criteria were assigned to treatment and ear to receive 
first injection in blocks of 2 without regard to parity. 
Treatments were saline (1.5 mL of sterile saline for in-
jection/45.5 kg of BW) or CCFA-SS [1.5 mL of 200-mg 
CE/mL of CCFA-SS per 45.5 kg of BW (6.6-mg CE/
kg of BW); Pfizer Animal Health Inc.; http://pfizerah.
com]. All personnel at each site who were involved in 
the study, except the treatment administrator, were 
blinded to treatment and the treatment administrator 
performed no other study-related activities.
Cows and Enrollment
Cows from 15 commercial dairies located through-
out the United States were included in the study from 
June through October, 2006. The rectal temperature 
(GLA M700 thermometer with M207 probe; GLA 
Agricultural Products, San Luis Obispo, CA; http://
www.gla-ag.com) of all potentially eligible cows that 
had calved at each study location through 10 d post-
calving (from d 1 to 10 postcalving) was determined 
daily each morning. Electronic medical histories (e.g., 
Dairy Comp 305, DHIA Plus) of cows with rectal tem-
peratures ≥39.5°C were reviewed to determine that 
cows did or did not meet exclusion criteria. Exclusion 
criteria were (1) administration, since calving, of any 
product containing antimicrobial (other than topical), 
steroidal, or nonsteroidal antiinflammatory, estrogenic, 
antipyretic, oxytocin, or prostaglandin agents; (2) ad-
ministration of antimicrobials other than topical during 
the 14 d immediately before parturition; (3) caesarian 
section delivery, fetotomy, or uterine prolapse at the 
most recent calving; and (4) retained fetal membranes 
and treatment with antimicrobials by either intrauter-
ine or parenteral routes at the most recent calving. 
The investigator evaluated vaginal discharge present 
on the rear of the animal and if none was present, a 
sample of discharge was obtained using a gloved hand 
in the vagina or use of a Metricheck device (Simcro, 
Hamilton, New Zealand; http://www.simcro.com) and 
determined the vaginal discharge score using the fol-
lowing scoring system: 0 = no discharge observed; 1 = 
not fetid, normal lochia, viscous, red, brown, or clear; 2 
= not fetid, thick mucus, cloudy, clearing, or clear; 3 = 
not fetid, may be purulent or mucopurulent, chocolate 
brown; and 4 = fetid, thin, serous, or watery, may have 
been red/pink (tomato soup) to chocolate brown, with 
or without pieces of necrotic tissue present. Cows with 
a vaginal discharge score of 4 were subjected to a physi-
cal exam conducted by a veterinarian to determine if 
conditions were present that might cause elevated rectal 
temperature or affect the response to treatment such 
as vaginal tears, traumatic gastritis, gastroenteritis, 
displaced abomasum, hemorrhagic septicemia, compli-
cated pneumonia, or laminitis. Assigned treatment was 
administered by s.c. injection in the posterior aspect 
of the ear where it attaches to the head (base of the 
ear) with the first dose administered on study d 0 and 
the second dose administered in the contra lateral ear 
on study d 3. To determine dose volume of saline or 
CCFA-SS, the BW of each cow was estimated using a 
breed-specific heart girth measuring tape (Nasco Inc., 
Atkinson, WI).
Measurements
Postinjection Indices. Immediately after injec-
tion, the treatment administrator evaluated the injec-
tion process using 3 indices: animal restraint, injection 
procedure index, and postinjection problem index. The 
scoring system for animal restraint was 0 = normal, 
injection administered without additional restraint 
(normal restraint consisted of procedures routinely 
used for injection into the jugular vein, such as neck 
lock-ups plus use of a halter or nose leads/tongs, among 
others) or 1 = additional restraint required. The scor-
ing system for the injection procedure was 0 = normal 
or 1 = required reinjection, due to animal movement 
(the needle needed to be re-inserted into the base of the 
ear). The scoring system for the postinjection problem 
was 0 = none, 1 = bleeding, 2 = leak back of injected 
material, 3 = bleeding and leak back of injected mate-
rial, and 4 = other.
Rectal Temperatures and Daily Observations. 
Rectal temperatures were measured before noon at the 
same time of day, specific for each dairy, on study d 1, 
2, 3, and 4. Cows were observed daily from study d 1 
to 13 for abnormal clinical signs (e.g., dehydration, an-
orexia, weakness, or severe depression) and the investi-
gator was notified of animals showing these signs. Some 
therapies including fluid supportive therapies of sodium 
chloride, dextrose, propylene glycol, Ringer’s lactate, 
among others, could be administered at any time with-
out removing animals from the study. Local anesthetics 
and topical antimicrobials could be administered for 
minor surgical repairs of wounds or teat surgeries and 
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calcium supplementation was permitted for cows with 
a diagnosis of milk fever. Animals that developed con-
ditions secondary to acute postpartum metritis, such 
as mastitis, displaced abomasum, and ketosis could re-
ceive supplemental therapy as follows and remained in 
the study and were not considered treatment failures. 
Mastitis could be treated only by frequent milkings. 
Displaced abomasum could be treated surgically and 
or with laxatives; topical antimicrobials could be used, 
but only regional anesthesia (e.g., line block) could be 
used if treated surgically. Ketosis could be treated with 
propylene glycol, dextrose, and B vitamins as needed. 
Dexamethasone or Predef Sterile Suspension or Ster-
ile Solution (Predef SS, isoflupredone acetate; Pfizer 
Animal Health Inc.; http://pfizerah.com) could be ad-
ministered, if needed, following label dosing directions. 
Dexamethasone could be administered only once and 
Predef SS could be administered only twice. However, 
neither dexamethasone nor Predef SS was permitted to 
be administered on d 11 to 14. Animals requiring more 
aggressive treatments were declared treatment failures 
and escape therapy was administered.
Physical Examinations. Physical examinations 
were conducted by a veterinarian on study d 5 or 6, 14, 
and 57 ± 3. On study d 5 or 6, rectal temperature and 
vaginal discharge score were recorded and, based on 
this information, the veterinarian determined if the cow 
was to remain in the study or be declared a treatment 
failure so that escape therapy could be administered. 
Criteria for removal included declining physical or clini-
cal condition such as dehydration, anorexia, weakness, 
severe depression, or any other clinical signs attribut-
able to toxic metritis with or without associated per-
sistent rectal temperature ≥39.5°C. Cows with a rectal 
temperature ≥39.5°C or a vaginal discharge score of 4 
could not be removed without additional clinical signs. 
Cows removed from the study received escape therapy, 
and had an exit examination which documented reason 
for removal.
On study d 14, rectal temperature and vaginal 
discharge score were determined for each cow that re-
mained in the study and were not considered treatment 
failures. Once during study d 57 ± 3 a clinical evalua-
tion of normal or abnormal was made for each surviv-
ing cow; any observation of abnormal was described.
Injection Site Evaluations. On study d 5 or 6, 14, 
and 57 ± 3, ears of all surviving cows were evaluated, 
including cows previously removed from the efficacy 
portion of the study (study d 1 to 14) after physical ex-
aminations. The site of injection at the base of each ear 
and the adjacent facial and auricular muscles within 
an approximate 2.5-cm radius of the injection site were 
observed and palpated and the following scoring system 
was used to evaluate injection sites: 0 = normal, no 
swelling or fluid detected; 1 = swelling or fluid, well 
defined, 2.5 to 5 cm in diameter detected; 2 = swelling 
or fluid, well defined, greater than 5 cm in diameter 
detected; 3 = diffuse swelling or fluid detected; 4 = 
ruptured, draining wound; and 5 = other. In addition, 
the carriage of each ear was also observed and scored as 
either normal or dropped (droopy).
Study d 14 to 57 ± 3. After the physical examina-
tion on study d 14 was completed, cows were subjected 
to the normal herd health program at each study loca-
tion and all medical interventions were documented. 
The only reasons cows could be removed from the study 
during this period were for death or euthanasia. In 
event of death, a necropsy was conducted.
Statistical Analysis
Clinical Cure Rate. Clinical cure rate, the measure 
of treatment efficacy, was based on information col-
lected on study d 14. Clinical cure was defined as rectal 
temperature <39.5°C, vaginal discharge score ≤3 (not 
fetid), and no escape therapy administered. A failure 
to cure was defined as temperature ≥39.5°C or vaginal 
discharge score = 4 (fetid), or both, or administration 
of escape therapy. In addition, animals that died or were 
moribund due to acute metritis were considered failures 
to cure. For statistical analysis, each animal was as-
signed a value of 0 (failure) or 1 (clinical cure). Animals 
that received concomitant antimicrobial or antiinflam-
matory therapy administered for a condition not related 
to acute metritis; animals that died, were euthanized, 
or culled for a condition not related to acute metritis; 
or animals that were associated with a deviation from 
protocol were censored from the efficacy analysis. Clini-
cal cure rate was analyzed using a generalized linear 
mixed model (GLMM); the macro GLIMMIX in SAS 
(SAS Institute, 2003) was used with a binomial error 
and logit link. Within this model, treatment was the 
fixed effect, whereas dairy farm, treatment by dairy 
farm, and residual were random effects. The analysis 
used the penalized quasi-likelihood approach with re-
stricted maximum likelihood estimation of the variance 
components. Efficacy was determined by comparing 
the CCFA-SS group with the saline group at a 2-sided 
significance level of 0.05.
Rectal Temperatures. Rectal temperatures during 
study d 0 to 5 or 6 were analyzed using a repeated 
measures ANOVA (SAS Institute, 2003). The model in-
cluded treatment, time, and treatment by time as fixed 
effects. The random effects included dairy farm, dairy 
farm by treatment, between-animal error, and dairy 
farm by treatment by time. The variance-covariance 
structure of the repeated measures was fit to at least 
the following models: compound symmetry, heteroge-
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neous compound symmetry, and unstructured. The 
unstructured model had the best Akaike information 
criterion and was chosen as the final model.
Injection Site and Ear Carriage Scores. Ear 
injection site and ear carriage scores were summarized 
by study day (5 or 6, 14, or 57 ± 3), within treatment 
group (CCFA-SS or saline) and by side injected (first 
and second). The percent normal scores were analyzed 
by side injected using a generalized linear mixed model 
with a binomial error and logit link (PROC GLIMMIX, 
SAS 9.2; SAS Institute, 2009). The fixed effects in the 
model were treatment, time, and treatment by time 
interaction. The random effects were dairy farm, dairy 
farm by treatment, between-animal error, and dairy 
farm by treatment by time.
Animal Restraint Index, Injection Procedure 
Index, and Postinjection Problem Index. Animal 
restraint index, injection procedure index, and postin-
jection problem index were summarized by treatment 
group (CCFA-SS or saline) and by side injected (first 
and second). The percent normal restraint, normal 
injection procedure, and no postinjection problem 
were analyzed by side injected using a generalized lin-
ear mixed model with a binomial error and logit link 
(PROC GLIMMIX, SAS 9.2; SAS Institute, 2009). The 
fixed effect was treatment and random effects were 
dairy farm and dairy farm by treatment.
Adverse Events. The number of animals having an 
adverse event and total number of events were sum-
marized by event category and treatment. The percent 
of animals ever having any adverse event was analyzed 
using a generalized linear mixed model with binomial 
error and logit link (PROC GLIMMIX, SAS 9.2; SAS 
Institute, 2009). The fixed effect was treatment and 
random effects were dairy farm and dairy farm by 
treatment. The number of adverse events per animal 
was log transformed [Ln(X+1)] and analyzed using a 
general linear mixed model. The fixed effect was treat-
ment and random effects were dairy farm, dairy farm 
by treatment, and residual.
RESULTS
Enrollment was discontinued at 2 sites at the same 
week that enrollment was completed at the last of the 
remaining 13 study sites because the expected calv-
ing rates indicated that it would be weeks to several 
months before the full 70 cows would be enrolled. The 
remaining 13 clinical sites each enrolled between 33 and 
37 cows per treatment group for a total of 1,023 cows. 
Seven cows were completely censored from all statisti-
cal analyses and data summaries due to deviations to 
the protocol. Deviations included items such as missed 
physical exams and incorrect treatment or treatment 
dose administration. Another 34 cows were removed 
from the statistical analysis for effectiveness due to 
deviations from the protocol or for a medical condition 
(adverse event) not related to metritis.
Clinical cure rate was greater (P < 0.0001) for cows 
administered CCFA-SS than for cows administered sa-
line (74.3 vs. 55.3% back-transformed LSM). Significant 
effects of treatment, day, and treatment by day interac-
tion on rectal temperature were observed (Figure 1). 
The rectal temperature of cows administered CCFA-SS 
was lower (P ≤ 0.0003) than that of cows administered 
saline on each of study d 1 to 5 or 6.
Normal restraint equipment was adequate to inject 
treatments at the base of the ear for ≥98.8% of both 
first and second injections and no difference (P ≥ 0.62) 
existed between percentage normal restraint for animals 
administered CCFA-SS compared with saline (Table 1). 
In addition, ≥97.1% of both first and second injections 
(saline and CCFA-SS) were made without need for re-
injection due to animal movement and no difference (P 
≥ 0.16) existed between percentage normal injection 
procedure for animals administered CCFA-SS com-
pared with saline (Table 1). The postinjection problem 
index categories were none, bleeding, leak back of in-
jected material, both bleeding and leak back, or other. 
No postinjection problems (score = 0) were observed 
in ≥85.8% of all doses administered (Table 1) and no 
difference existed in percentage of no postinjection 
problem between CCFA-SS and saline (P ≥ 0.3445).
Percentages of normal injection site scores are pre-
sented in Table 2. Statistical differences existed between 
Figure 1. Average rectal temperatures (LSM ± SEM) for study d 
0 to 5 or 6 after enrollment for cows treated with 1.5 mL of saline/45.5 
kg of BW or 6.6-mg ceftiofur equivalents (CE) of ceftiofur crystalline 
free acid sterile suspension (CCFA-SS)/kg of BW. Effect of treatment: 
P < 0.0001, day of study: P < 0.0001, and treatment by day of study: 
P < 0.0001. **CCFA-SS was different from saline within day (P ≤ 
0.0003).
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treatments (P ≤ 0.0004) and study day (P ≤ 0.0001) 
for both the first and second injection, which were ana-
lyzed separately. For the second day of injection, the 
interval to observation was 2 or 3 d for study d 6 and 
11 d for study d 14. Percentages of normal injection site 
scores were less (P ≤ 0.0028) for CCFA-SS than saline 
for both first and second injections on study d 5 or 6 
and 14. By d 57 ± 3, percentage normal injection site 
scores after both the first or second injection did not 
differ (P ≥ 0.27) between CCFA-SS and saline.
Percentages of normal ear carriage scores are sum-
marized in Table 3. No differences (P ≥ 0.070) were 
observed in percentages of normal scores between 
CCFA-SS and saline at any time point.
One cow died immediately (15–20 min) following 
administration of a second dose (19 mL) of CCFA-SS. 
Necropsy results led to the conclusion that the probable 
cause of death was intraarterial injection of CCFA-SS. 
Adverse health events not related to acute metritis are 
summarized by general category and treatment group 
in Table 4. Independently of event category, the num-
ber of cows that had an adverse event and the number 
of adverse events per cow did not differ between treat-
ment groups (P ≥ 0.11).
Table 1. Percentages1 of normal (score = 0) animal restraint index scores, injection procedure index scores, and postinjection problem index 
scores for cows treated with 1.5 mL of saline/45.5 kg of BW or 6.6-mg ceftiofur equivalents (CE) of ceftiofur crystalline free acid sterile 
suspension (CCFA-SS2)/kg of BW 
Side injected
Treatment group
P-value
Saline CCFA-SS
No. of cows % 0 scores No. of cows % 0 scores
Animal restraint index score3
 First 503 98.8 ± 0.6 504 99.1 ± 0.5 0.62
 Second 472 98.9 ± 0.5 493 98.9 ± 0.5 0.96
Injection procedure index score4
 First 504 98.3 ± 0.6 506 97.1 ± 0.9 0.16
 Second 474 98.7 ± 0.6 497 97.8 ± 0.8 0.30
Post-injection problem index score5
 First 504 87.8 ± 4.4 507 85.8 ± 5.0 0.39
 Second 473 92.4 ± 3.8 494 90.7 ± 4.6 0.34
1Back-transformed LSM ± SEM.
2Pfizer Animal Health, New York, NY.
3Animal restraint index score: 0 = normal restraint; 1 = additional restraint needed.
4Injection procedure index score: 0 = normal; 1 = reinjection needed due to animal movement.
5Postinjection problem index score: 0 = none; 1 = bleeding; 2 = leak back of injected material; 3 = bleeding and leak back of injected material; 
4 = other.
Table 2. Percentages of normal1 (score = 0) ear injection site scores for the first and second injected ear of cows treated with 1.5 mL of 
saline/45.5 kg of BW or 6.6-mg ceftiofur equivalents (CE) of ceftiofur crystalline free acid sterile suspension (CCFA-SS2)/kg of BW3 
Side injected
Treatment group
P-value
Saline CCFA-SS
No. of cows % normal scores No. of cows % normal scores
d 5 or 6 (2 or 3)
 First 493 85.5 ± 5.6 497 64.2 ± 10.1 0.0020
 Second 493 81.1 ± 6.3 497 51.9 ± 10.1 <0.0001
d 14 (11)
 First 478 96.0 ± 1.8 488 87.3 ± 5.0 0.0028
 Second 478 93.2 ± 2.8 488 79.6 ± 6.7 0.0002
d 57 ± 3 (54 ± 3)
 First 453 99.9 ± 0.1 475 99.7 ± 0.2 0.27
 Second 453 98.9 ± 0.6 475 98.6 ± 0.8 0.63
1Back-transformed LSM ± SEM.
2Pfizer Animal Health, New York, NY.
3Numbers in parentheses are the days between administration of the second dose and the observation.
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DISCUSSION
The results of this clinical trial demonstrate that 2 
treatments of CCFA-SS given at the base of the ear 
72 h apart to cows with metritis, as defined by rectal 
temperature ≥39.5°C and fetid vaginal discharge, in-
creased the clinical cure rate 19% compared with saline 
controls. This increase in clinical cure rate is similar 
to that demonstrated with ceftiofur administered daily 
as well as other antibiotic treatments. Chenault et al. 
(2004) reported a 15% increase in clinical cure rate com-
pared with controls at 14 d after 5 daily injections of 
2.2-mg CE of ceftiofur hydrochloride/kg of BW in cows 
enrolled with a rectal temperature ≥39.5°C and fetid 
vaginal discharge. Zhou et al. (2001) reported that cure 
rate was increased 23.3% by d 10 with 3-d administra-
tion of 1-mg CE of ceftiofur hydrochloride or sodium/
kg of BW to cows enrolled with rectal temperature 
≥39.5°C that also had a vaginal discharge at enroll-
ment. Drillich et al. (2001) found that cure rates based 
on rectal temperature <39.5°C on d 6 for cows with 
toxic puerperal metritis were similar for treatments of 
2.2-mg CE of ceftiofur sodium/kg of BW for 3 d with or 
without intrauterine antibiotics (2,500 mg of ampicillin 
and 600 mg of cloxacillin) and intrauterine antibiotics 
plus 600 mg of ampicillin i.m. for 3 d. The cure rates of 
metritis (82.9 to 84.8%) were numerically higher than 
those in the present study (74.3% for CCFA-SS).
The effects of CCFA-SS treatment on rectal tem-
peratures during the first 5 or 6 d of the study were 
similar to those observed by others. Chenault et al. 
(2004) reported that rectal temperature was decreased 
during 5 d of treatment with either 1.1 or 2.2-mg CE 
of ceftiofur hydrochloride/kg of BW and the decrease 
was approximately 0.9°C from d 1 to 5 for both treat-
ments. Smith et al. (1998) observed a 0.7°C drop in rec-
Table 3. Percentages of normal1 (score = 0) ear carriage scores for the first and second injected ears of cows treated with 1.5 mL of saline/45.5 
kg of BW or 6.6-mg ceftiofur equivalents (CE) of ceftiofur crystalline free acid sterile suspension (CCFA-SS2)/kg of BW3 
Side injected
Treatment group
P-value
Saline CCFA-SS
No. of cows % normal scores No. of cows % normal scores
d 5 or 6 (2 or 3)
 First 493 99.5 ± 0.3 496 98.3 ± 1.1 0.070
 Second 493 98.8 ± 0.7 496 96.6 ± 1.6 0.093
d 14 (11)
 First 478 99.7 ± 0.2 488 99.7 ± 0.3 0.78
 Second 478 99.1 ± 0.5 488 98.7 ± 0.7 0.59
d 57 ± 3 (54 ± 3)
 First 453 99.8 ± 0.2 475 99.8 ± 0.1 0.76
 Second 453 99.7 ± 0.2 475 99.8 ± 0.1 0.56
1Back-transformed LSM ± SEM.
2Pfizer Animal Health, New York, NY.
3Numbers in parentheses are the days between administration of the second dose and the observation.
Table 4. Numbers of cows with adverse health events (AE) for cows treated with 1.5 mL of saline/45.5 kg 
of BW or 6.6-mg ceftiofur equivalents (CE) of ceftiofur crystalline free acid sterile suspension (CCFA-SS1)/
kg of BW 
Event category
No. of cows No. of AE/cow
Control CCFA-SS Control CCFA-SS
Mastitis after d 14 20 14 28 19
Pneumonia 13 10 15 11
Gastrointestinal tract 10 10 11 10
Foot/leg 23 13 25 15
Injury 3 9 4 12
Other 18 8 22 8
Mean2 13.9 ± 2.4 10.6 ± 2.0 0.13 ± 0.003 0.10 ± 0.002
P-value3 0.14 0.11
1Pfizer Animal Health, New York, NY.
2Back-transformed LSM ± SEM for percent of cows that had any AE (yes or no) and for number of AE per 
cow.
3CCFA-SS compared with control for no. of cows or no. of AE/cow.
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tal temperature from d 1 to d 5 for cows treated with 
2.2-mg CE of ceftiofur sodium/kg of BW i.m. for 5 d. 
Cows in that study were diagnosed with toxic puerperal 
metritis based on criteria of rectal temperature >39°C, 
uterine physical condition, fetid vulvar discharge, and 
depressed milk yield.
No uterine samples were taken to evaluate bacterial 
population, but the increased clinical cure rate would 
suggest that concentrations of ceftiofur derivatives were 
sufficiently high for sufficiently long to reduce metritis 
defined, in part, by the presence of uterine discharge. 
Witte et al. (2011) showed that a single injection of 
CCFA-SS in healthy cows resulted in ceftiofur deriva-
tive concentrations in serum and endometrial tissue 
that were above reported minimum concentrations re-
quired to inhibit relevant pathogens such as E. coli and 
A. pyogenes (0.5 and 0.125 μg/mL, respectively) over 
a 7-d period (Okker et al., 2002; Sheldon et al., 2004a; 
Drillich et al., 2006).
The safety of 2 treatments with CCFA-SS 3 d apart 
was evaluated by scoring the injection procedure and 
injection site appearance. Normal restraint and no rein-
jection were adequate for ≥97.1% of the injections. The 
injection procedure was further evaluated by observa-
tion of the base of the ear immediately after treatment 
administration. Greater than or equal to 85.8% of the 
cows were normal at the site, although some animals 
had bleeding and leak back of material, and effects were 
similar for CCFA-SS and for saline.
The safety of CCFA-SS injection was further evalu-
ated by scoring the base of the ear treatment admin-
istration sites approximately 1, 2, and 8 wk after the 
first of the 2 treatments. The average percentages of 
normal scores during the first and second weeks were 
approximately 25 and 10%, respectively, lower for the 
CCFA-SS than saline cows and were higher for the 
first than the second injection, whereas no differences 
were observed between treatment and injection dur-
ing the eighth week. This indicates that even saline 
administered s.c. in the base of the ear also elicits a 
site reaction, albeit less than that to CCFA-SS. By 14 
or 11 d after the first or second injection of CCFA-SS, 
respectively, 79.6% or more of the sites were normal. 
The percentages of normal ear carriage scores for both 
treatments were ≥96.6 throughout the study.
The fact that 1 of the approximately 500 cows given 
approximately 1,000 injections (0.1%) died very soon 
after administration of CCFA-SS is consistent with the 
warning on the label for CCFA-SS that injection of 
CCFA-SS into the arteries of the ear is likely to cause 
sudden death. This happens at a very low rate and 
is likely due to inadvertently administering treatment 
intraarterially.
CONCLUSIONS
Two doses of CCFA-SS (6.6-mg CE/kg of BW) at a 
72-h interval provide a safe and effective treatment of 
acute postpartum metritis in dairy cattle.
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